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Organometallic complexes offer chemistry that is not accessible to
purely organic molecules and, hence, potentially new mechanisms
of drug action. We show here that the presence of both an iodido
ligand and a-donor/-acceptor phenylazopyridine ligand confers
remarkable inertness toward ligand substitution on the half-sand-
wich ‘‘piano-stool’’ ruthenium arene complexes [(6-arene)Ru(az-
py)I] (where arene  p-cymene or biphenyl, and azpy  N,N-
dimethylphenyl- or hydroxyphenyl-azopyridine) in aqueous
solution. Surprisingly, despite this inertness, these complexes are
highly cytotoxic to human ovarian A2780 and human lung A549
cancer cells. Fluorescence-trapping experiments in A549 cells sug-
gest that the cytotoxicity arises from an increase in reactive oxygen
species. Redox activity of these azopyridine RuII complexes was
confirmed by electrochemical measurements. The first one-elec-
tron reduction step (half-wave potential 0.2 to 0.4 V) is assign-
able to reduction of the azo group of the ligand. In contrast, the
unbound azopyridine ligands are not readily reduced. Intriguingly
the ruthenium complex acted as a catalyst in reactions with the
tripeptide glutathione (-L-Glu-L-Cys-Gly), a strong reducing agent
present in cells at millimolar concentrations; millimolar amounts of
glutathione were oxidized to glutathione disulfide in the presence
of micromolar ruthenium concentrations. A redox cycle involving
glutathione attack on the azo bond of coordinated azopyridine is
proposed. Such ligand-based redox reactions provide new con-
cepts for the design of catalytic drugs.
arenes  cytotoxicity  glutathione  redox reactions 
ruthenium complexes
Organometallic complexes offer potential for the develop-ment of new materials with a wide range of applications (1,
2). Organometallic complexes can exhibit chemical reactivity not
possessed by either the metal or organic ligands alone and this
reactivity can be fine-tuned by subtle changes in the electronic
and steric properties of the bound ligands, or by variation of the
metal and its oxidation state. These features provide a versatile
platform for drug design that is now being exploited in several
areas. For example, the redox activity of the organometallic
ferrocenylphenol substitutents enhances the anticancer activity
of tamoxifen derivatives by conferring an ability to generate
reactive oxygen species in cells (3). Here we consider the
anticancer activity of ruthenium(II) arene complexes. Such
complexes are well known as catalysts in industry, for example,
for hydrogenation reactions (4). Although organometallic com-
plexes can catalyze hydrogenation of intracellular biomolecules
(5), metal-centered catalysts might be readily poisoned and be
ineffective in biological media.
Organometallic half-sandwich RuII arenes of the type [(6-
arene)Ru(YZ)(X)] where YZ is typically a chelating diamine
ligand (e.g., ethylenediamine, en) and X is a halide (e.g., Cl)
exhibit anticancer activity in vitro and in vivo (6, 7). As with many
metal-based anticancer drugs, the primary cellular target is
thought to be DNA. The Ru–Cl bond is labile, but hydrolysis is
suppressed extracellularly because of the high chloride concen-
tration, 104 mM (8). The intracellular chloride concentration
is much lower, and hydrolysis can generate a reactive site on
ruthenium (Ru-OH2) for subsequent DNA binding. DNA bind-
ing leads to further ‘‘downstream’’ effects, ultimately resulting in
cell death (9, 10). Changing the chelating ligand has dramatic
effects on cytotoxicity, which is also influenced by the nature of
the arene ligand (11). In this series of diamine complexes,
changing the monodentate ligand X from chloride to iodide has
little effect on activity; both are good leaving groups (12). This
contrasts dramatically with the chlorido and iodido rutheni-
um(II) arene complexes reported here, which contain -donor/
-acceptor 2-phenylazopyridines as N,N-chelating (YZ) ligands.
Unlike their en analogues, these complexes exhibit different
solution chemistry, and a different mechanism of cancer cell
cytotoxicity, involving catalytic redox reactions.
Results
Complexes. We synthesized and characterized RuII complexes
containing either p-cymene (complexes 1–3) or biphenyl (com-
plexes 4–6) as the -bonded arene, a bidentate phenylazopyri-
dine ligand having either NMe2, OH, or H as para substituent on
the phenyl ring, and I as the monodentate ligand (Fig. 1). The
molecular structure of complex 4MeOH was determined by
x-ray crystallography [see supporting information (SI) Fig. S1].
Significant bond lengths and angles are reported in the SI Text
(Table S1). The Ru–N bond lengths are comparable to analo-
gous RuII arene phenylazopyridine chlorido complexes (13), as
are the ruthenium-arene carbon distances (13). The Ru–I bond
length [2.6984 (5) Å] is slightly shorter than in ruthenium(II)
arene structures containing ethylenediamine as the chelating
ligand {2.7116 (7) Å for [(6-hexamethylbenzene)Ru(en)I] and
2.7166 (7) Å for [(6-indan)Ru(en)I] (12)}. These phenylazo-
pyridine complexes possess ‘‘3-legged piano-stool’’ structures
and are intensely colored as a result of RuII-to-ligand (4d6-*)
charge-transfer and intraligand –* transitions (13).
Cytotoxicity. Complexes 1, 2, 4, and 5 containing p-cymene or
biphenyl as arene and electron-donating groups (OH, NMe2) on
the phenylazopyridine ligand were highly cytotoxic to A2780
human ovarian and the A549 human lung cancer cell lines with
IC50 values of 2–6 M, whereas complexes 3 (IC50 100 M)
and 6 (IC50 40–50 M), containing an unsubstituted pheny-
lazopyridine ligand were much less cytotoxic (Table 1). Replace-
ment of iodide by chloride led to a dramatic decrease in
cytotoxicity (13), and the 2-phenylazopyridine ligands alone
were relatively nontoxic, with the exception of Azpy-NMe2 in the
A549 cell line (Table 1).
Author contributions: S.J.D., A.H., and P.J.S. designed research; S.J.D., A.H., and S.E.M.
performed research; S.E.M. and S.P. contributed new reagents/analytic tools; S.J.D., A.H.,
S.E.M., S.P., and P.J.S. analyzed data; and S.J.D., A.H., S.P., and P.J.S. wrote the paper.
Conflict of interest statement: The University of Edinburgh has filed a patent application
relating to these ruthenium complexes. This has been licensed to Oncosense Ltd.
This article is a PNAS Direct Submission.
Freely available online through the PNAS open access option.
Data deposition: The atomic coordinates have been deposited in the Cambridge Structural
Database, Cambridge Crystallographic Data Centre, Cambridge CB2 1EZ, United Kingdom
(CSD reference no. 671-850). The x-ray crystallographic data for complex 4 can be found in
SI Text.
§To whom correspondence should be addressed. E-mail: p.j.sadler@warwick.ac.uk.
This article contains supporting information online at www.pnas.org/cgi/content/full/
0800076105/DCSupplemental.
© 2008 by The National Academy of Sciences of the USA
11628–11633  PNAS  August 19, 2008  vol. 105  no. 33 www.pnas.orgcgidoi10.1073pnas.0800076105
Solution Chemistry.We investigated whether the complexes could
undergo activation by hydrolysis. We used conditions that mimic
the concentration, pH, exposure time, and temperature used in
biological cell tests, and thus monitored 100 M solutions of the
complexes in 10 mMphosphate buffer (containing 95%D2O/5%
MeOD, pH 7.3) and at 310 K over 24 h by 1H NMR. For iodido
complexes 1, 2, 4, and 5 containing phenylazopyridine ligands
with OH or NMe2 substitutents, no changes in the spectra
occurred (e.g., Fig. S2 for complex 4) suggesting that no hydro-
lysis took place. This was confirmed by ESI-MS studies of the
NMR sample where only the intact cation was detected [1, m/z
found 588.75 (M), calcd 589.04; 2,m/z found 561.70 (M), calcd
561.99; 4, m/z found 608.71 (M), calcd 609.03; 5, m/z found
581.65 (M), calcd 581.98]. However, the NMR spectra of the
unsubstituted phenylazopyridine complexes 3 and 6 changed
over the 24-h period (Figs. S3 and S4, respectively). For 6, all
peaks for the intact cation disappeared and the only assignable
peaks in the spectrum were due to free biphenyl. For 3, the peaks
for the intact cation decreased in intensity and peaks for free
p-cymene were observed. The slow decomposition of 3 and 6 (50
M, 10 mM phosphate buffer, 310 K, 24 h) was confirmed by
UV-Vis spectroscopy (Fig. S5).
Importantly, with 104 mMNaCl present (close to extracellular
[Cl]) no changes in the UV-Vis spectrum of complex 4 were
observed over 24 h at 310 K (see Fig. S6), suggesting that no
substitution of iodide by chloride takes place.
Electrochemical Reductions. In general, the complexes exhibited
two electrochemical reductions (in dimethylformamide), the
first at 0.2 to0.4 V and a second at 0.7 to1 V (Table
1). Reductions were also observed near to the solvent cutoff
( 2 V), but were not considered further.
In all cases the first reduction (confirmed as a one-electron
reduction for complex 3, n  0.98, Fig. S7) was essentially
irreversible (no reverse scan peak at 0.1 Vs1, Fig. S8). The
reduction potential becomes more positive as the arene is
changed from p-cymene to biphenyl and also as the chelating azo
ligand is changed from azpy-NMe2, to azpy-OH to azpy (Table
1). Based on literature assignments for other ruthenium–
phenylazopyridine complexes (14, 15), this reduction can be
assigned to addition of an electron into the * orbital centered
on the azo group of the phenylazopyridine ligands to form the
azo anion radical (–NN–  e 3{–N–N–}). The relative
order therefore reflects the decreasing -acceptor capability of
the substituted azpy ligands with the addition of electron-
donating groups onto the phenyl ring (16). The irreversible
second reduction step is assigned to conversion to the dianionic
species ({–N–N–}2). Azo groups usually give rise to two
separate electrochemical reductions in polar aprotic solvents
(17). In aqueous media the two-electron reduction of azo groups
is accompanied by proton transfer to give hydrazo groups
(NH–NH) in a single step (17).
Reactions with Glutathione. In cells, the major reducing agent is
the tripeptide glutathione (GSH), a thiol present at millimolar
concentrations (18). We were thus interested to follow the
reactions of the ruthenium complexes with GSH. HPLC and
electrospray ionization (ESI)-MS studies showed that the initial
step in the reaction of excess GSH with [(6-biphenyl)Ru(azpy-
NMe2)I]PF6, complex 4, and the corresponding chlorido com-
plex involves complete substitution of halide by GS, to give
[(6-biphenyl)Ru(azpy-NMe2)GS] (m/z obs 788.0, calcd 789.2;
Fig. S9). Half-lives for this substitution were determined as 1.3
min (kobs  8.73  103 s1) for the chlorido complex 4-Cl, and
17.5 min for the iodido complex 4 (kobs  6.58  104 s1; 298
K by UV-Vis spectroscopy). Thus iodide substitution by GS
occurs 14 times more slowly than chloride substitution. During
1H NMR studies of reactions of [(6-biphenyl)Ru(azpy-
NMe2)I]PF6, 4, and [(6-biphenyl)Ru(azpy-OH)I]PF6, 5, with
glutathione (carried out in deoxygenated solutions under N2 or
Ar to avoid autoxidation), it became apparent that these com-
plexes can act as catalysts for the oxidation of GSH to GSSG.
The NMR spectra showed that incubation of 10 mMGSHwith
100 M 4 or 5 (in 10 mM phosphate, pH 7.2, 85% H2O, 10%
D2O, 5% acetone-d6, 310 K, followed over 24 h) led to a steady
oxidation of 3.7 mM (turnover frequency 0.30 h1, R2 0.98)
and 4.6 mM, (turnover frequency  0.37 h1, R2  0.99),
respectively, of GSH to GSSG (Fig. S10), as evidenced by the
appearance of new peaks at  3.30 ppm corresponding to the
-CH2 of GSSG (Fig. S10 Inset). The formation of GSSG was
further confirmed by ESI-MS spectra of these solutions after
24 h incubation, which showed peaks consistent with the pres-
ence of glutathione (m/z obs 305.2, calcd for GS 305.1) and
glutathione disulfide (m/z obs 611.1, calcd for GSSG 611.2).
LC-MS attempts to detect intermediates in the catalytic cycle
were unsuccessful, probably because they are transient. Inter-
estingly, bubbles formed in the reaction tubes during the course
of the reaction, suggesting that a gas had been produced. A
variety of methods were used in attempts to detect H2 during the
course of the reaction (colorimetric assays, NMR, and gas
chromatography). However, none of these led to H2 detection
(see SI Text). The GC analysis showed that small amounts of O2
were present in the head space of reactions despite thorough
initial purging with N2 or Ar. No H2O2 was detected in the
reaction mixtures by using peroxide test sticks.
RuN
N I
PF6
N
1: R = NMe2
2: R = OH
3: R = H
4: R = NMe2
5: R = OH
6: R = H
R
RuN
N I
N
R
PF6
Fig. 1. Structures of complexes synthesized in this work.
Table 1. IC50 values (M) for [(6-arene)Ru(azpy-R)I]PF6
complexes, their corresponding chloride analogues
[(6-arene)Ru(azpy-R)Cl]PF6 and free phenylazopyridine ligands
for A2780 ovarian and A549 lung cancer cell lines, and the first
and second (where observed) electrochemical reduction
potentials (DMF vs. Ag/AgCl)
Complex*
IC50, M
Ered, VA2780 A549
1 (1-Cl) 4 (100) 3 (100) 0.40, 1.00
4 (4-Cl) 3 (44) 2 (49) 0.36
Azpy-NMe2 100 14 1.28
2 (2-Cl) 4 (58) 4 (100) 0.33, 0.77
5 (5-Cl) 5 (18) 6 (56) 0.26, 0.72
Azpy-OH 100 100 nd†
3 (3-Cl) 100 (100) 100 (100) 0.22, 0.74
6 (6-Cl) 39 (100) 51 (100) 0.18, 0.67
Azpy 100 100 1.31 (vs.SCE)‡
*Iodido complexes 1–6 (and their chlorido analogues 1-Cl to 6-Cl in parenthe-
ses).
†nd, not determined.
‡Ref. 14.
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Under similar conditions, neither of the free ligands Azpy-
NMe2 nor Azpy-OH caused any oxidation of GSH to GSSG.
Hence, the redox activity of 2-phenylazopyridine ligands de-
pends on being coordinated to ruthenium.
Detection of Reactive Oxygen Species (ROS) in A549 Cancer Cells. The
molecular probe 2,7-dichlorodihydrof luorescein-diacetate
(DCFH-DA) is taken up by live cells, is hydrolyzed to 2,7-
dichlorodihydrofluorescein (DCFH), and in the presence of
ROS is oxidized to highly fluorescent 2,7-dichlorofluorescein
(DCF) (19). This probe measures general oxidative stress (20).
Fig. 2 shows the increase in fluorescence detected over time after
A549 cancer cells were exposed to ruthenium compounds pre-
loaded with DCFH-DA. Compounds 1, 2, 4, and 5 all caused an
increase in DCF fluorescence with time, indicating that they all
increase the levels of ROS inside A549 cancer cells.
In contrast, the ethylenediamine chelates [(6-biphenyl)Ru-
(en)Cl]PF6 or [(6-tetrahydroanthracene)Ru(en)Cl]PF6 (Ru-A
and Ru-B, respectively, in Fig. 2) caused no increase in DCF
fluorescence, showing that these two compounds do not gener-
ate ROS.
The thiol levels in A549 cells were increased by preincubation
with 5 mM N-acetyl-L-cysteine (NAC). The cells were washed to
remove excess NAC before treatment with the complexes. Fig.
3 shows that after treatment with complexes 1, 2, 4, or 5 for 24 h
incubation followed by 96 h recovery time, there is greater cell
survival for the cells that have increased thiol levels, whereas
increased thiol levels had little effect on survival of cells treated
with cisplatin.
Discussion
Cytoxicity Without Hydrolysis.Many examples are known of metal
anticancer complexes containing metal–halide bonds that are
activated in cells by hydrolysis and subsequently bind to DNA as
a target, for example, PtII diam(m)ine complexes, including the
drug cisplatin (21), and diamino RuII arene complexes (22). In
contrast, the organometallic iodido RuII arene azopyridine
complexes studied in this article are inert toward hydrolysis and
yet are still cytotoxic.
For example, complexes 1, 2, 4, and 5 are all resistant to
hydrolysis over 24 h at 310 K and at micromolar concentrations
and physiological pH. Complexes containing unsubstituted azpy
(3 and 6) were not as cytotoxic toward the two cancer cell lines.
This low activity can be correlated with their instability in
phosphate-buffered solutions (Figs. S3–S5). High cytotoxicity is
therefore associated with iodido azopyridine complexes that are
highly stable in aqueous media. The corresponding chlorido azpy
complexes are much less stable in water, with slow hydrolysis of
both Ru–Cl and Ru–arene bonds occurring [t1/2 9–21 h (13)], and
these complexes are much less cytotoxic (Table 1). Iodide is less
electronegative than chloride, behaves more like a simple two-
electron donor, and forms stronger bonds to RuII. The increased
electron density at the ruthenium center is therefore available
for backdonation onto the arene, which also strengthens the
RuII–arene bonds. Hydrolysis rates of RuII arenes decrease when
a -acceptor-chelating ligand is incorporated into the complex,
as we have discussed elsewhere (13).
The dramatic increase in cytotoxicity of iodido complexes
compared with chlorido complexes observed here is not seen for
RuII arene complexes containing the -donor ethylenediamine
as the chelating ligand; compare, for example, [(6-benzene)Ru-
(en)Cl]PF6, IC50 17 M, [(6-benzene)Ru(en)I]PF6, IC50 20
M (12). In the case of ethylenediamine complexes, the Ru–I
bonds are converted to Ru–Cl bonds during the cytotoxicity
assays because of the large excess of NaCl in the cell culture
medium. In contrast, the iodido phenylazopyridine complexes do
not appear to react with excess NaCl (see Fig. S5 for 4).
The iodido complexes also react more slowly with GSH than
the chlorido complexes. In cells, GSH exerts a major protective
role as a detoxifier of electrophilic substances (E), such as
metals, forming thioether conjugates GS-E (18). These conju-
gates are eliminated via an ATP-dependent GS-E pump (23).
GS-conjugation is the major deactivation mechanism for plati-
num complexes such as cisplatin (24). The greater resistance of
the Ru–I bond to conjugation may further enhance their potency
compared with chlorido complexes.
Ligand-Based Redox Reactions. The coordination of phenylazopy-
ridine ligands to arene-ruthenium centers shifts their reduction
potentials to biologically accessible values and results in cyto-
toxic complexes. Phenylazopyridine ligands can accept two
electrons in one electrochemically accessible, lowest unoccupied
molecular orbital, which is primarily azo in character (25).
Coordination of these ligands to the dipositive ruthenium center
allows ligand-based reduction to occur at a much more positive
potential; the first electrochemical reduction for the free ligand
azpy-NMe2, for example, occurs at 1.28 V, compared with
0.40 V for complex 1 and 0.36 V for complex 4 (Table 1).
Catalytic Activity Toward Glutathione.Ruthenium complexes 4 and
5 oxidize GSH to GSSG catalytically, unlike the free ligands
azpy-NMe2 and azpy-OH. Here we have shown that under
physiologically relevant conditions micromolar concentrations
of organometallic azpy complexes can deplete millimolar
amounts of GSH over 24 h by catalytic oxidation to GSSG.
0 1 2 3 4 5 6
0
1
2
3
4
5
Time / h
(2)
(5)
(4)
(1)
H2O2
Ru-A
Ru-B
Control{
R
e
la
tiv
e 
Fl
uo
re
s
ce
n
c
e 
In
te
n
si
ty
 
(x 
10
3 )
Fig. 2. Relative increase in DCF fluorescence detected over time after
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A possible catalytic cycle for the conversion of GSH into
GSSG is shown in Fig. 4. The initial step involves the conju-
gation of GSH across the azo double bond and subsequent
reduction of the azo group to an hydrazo group with GSH
oxidation. Such a process is reported to occur for the azo
ester C6H5NNCOOCH3 (26) and for the diamide
(CH3)2NCONNCON(CH3)2 (27). However for these re-
ported reactions, a stoichiometric amount of complex is re-
quired, that is, the compounds are not catalytic. Because no H2
was detected during the course of the reaction, it seems likely
that the second step in which the azo NN group is regener-
ated, and the catalytic cycled is completed, proceeds via
concomitant hydrogenation of dissolved O2 to generate H2O2.
Given that no H2O2 was detected in the reaction mixture, it is
reasonable to propose that iodide (displaced from Ru by the
initial substitution reaction with GSH) causes its decomposi-
tion (I  H2O23 IO  H2O; IO  H2O23 I  H2O 
O2). Such catalytic behavior of iodide toward H2O2 is well
known (28) and explains the observed gas bubbles (O2).
Examples in the literature of azo groups facilitating the oxidation
of GSH include the Hodgkins and non-Hodgkins lymphoma drug
procarbazine [CH3NH–NHCH2C6H4CONHCH(CH3)2], an hy-
drazo compound that is easily oxidized to the corresponding azo
compound and re-reduced via GSH oxidation to GSSG (29). The
reoxidation of this hydrazo group is facilitated by O2 inside cells,
which is hydrogenated to form H2O2.
Oxidation of GSH to GSSG was not induced by the free
ligands. This is perhaps not surprising because electron-donating
groups attached to azo groups (here OH or NMe2) decrease
their ability to oxidize GSH (17). Coordination to RuII is
necessary to make the azo nitrogen atoms positive enough for
the redox reaction to occur.
Detection of Reactive Oxygen Species. The dichlorofluorescein
fluorescence experiments showed that the iodido RuII arene
N,N-dimethyl- and hydroxy-azopyridine complexes 1, 2, 4, and 5
cause a buildup of reactive oxygen species in A549 lung cancer
cells (Fig. 2). Reactive Oxygen Species (ROS) present a higher
reactivity than molecular oxygen (30), and encompass not only
free radicals such as the superoxide (O2
•), hydroperoxyl radical
(HO2
•) and the hydroxyl radical (HO•), but also hydrogen
peroxide (H2O2) and singlet oxygen (1O2). ROS are continuously
generated in small quantities during normal cellular processes
and are involved in several biological functions, such as cell
growth and signaling (30). Excessive ROS generation inside cells
is harmful, causing oxidation of biomolecules such as lipids, cell
membranes, proteins, and DNA, and giving rise to oxidative
stress (30). Importantly, no DCF fluorescence was detected for
ruthenium arene complexes containing ethylenediamine (en) as
chelating ligand, illustrating a fundamental difference in the
mechanism of action of these two classes (azpy/en) of cytotoxic
ruthenium arene complexes.
To assess the impact of ROS inside A549 lung cancer cells,
intracellular thiol levels were increased by adding the antioxidant
N-acetyl-L-cysteine, which is believed to act by raising intracel-
lular concentrations of cysteine and hence GSH, and also by
direct reaction of its thiol group with ROS (31). Treatment of
cells with N-acetyl-L-cysteine increased the survival of cells
treated with RuII arene phenylazopyridine compounds (Fig. 3)
providing evidence that ROS are implicated in cell death.
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Fig. 4. Proposed cycle for the catalytic oxidation of GSH to its corresponding disulfide GSSG by ruthenium(II) arene phenylazopyridine complexes. Initially X
is iodide, which is displaced by GS during the early stages. Released iodide can catalyze the decomposition of H2O2. Bound GSH at pH 7 has deprotonated thiol
and carboxyl groups, and a protonated amino group.
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Oxidative Stress Causes Cell Death. Oxidative stress is caused by a
serious imbalance between the levels of ROS in a cell and its
antioxidant defenses in favor of the former (20). On the basis
that GSH is the primary cellular antioxidant, it seems likely that
the depletion of antioxidants is the primary mechanism by which
ROS levels are increased and by which oxidative stress occurs in
the systems studied here. Because cancer cells (mainly multi-
drug-resistant cells) are more sensitive to the additional expo-
sure to ROS than normal cells (32), the proposal has been made
that ROS can be used therapeutically to treat cancer (27, 31).
Several established anticancer drugs are known to generate ROS
or other radicals, including adriamycin (33), arsenic trioxide
(34), and cisplatin (35).
Conclusions
Organometallic complexes present versatile platforms for drug
design. Appropriate choice of the metal, its oxidation state, and
the ligands can allow fine-tuning of the steric and electronic
properties of the complex and hence its biological activity and
mechanism of action. In the present case we have assembled RuII
complexes containing a -bonded arene ligand together with a
strongly chelated -donor/-acceptor azopyridine ligand and
iodide as a strongmonodentate ligand to produce complexes that
are relatively inert toward activation by hydrolysis and yet
potently cytotoxic toward cancer cells.
These azopyridine complexes undergo activation by reduction.
Whereas azopyridine ligands alone are difficult to reduce, the
reduction potentials are biologically accessible when the azopy-
ridine is coordinated to RuII. The complexes can induce redox
reactions inside cancer cells leading to an increase in the
accumulation of reactive oxygen species. Intriguingly iodido RuII
arene azopyridine complexes can act as catalysts for the oxida-
tion of the major intracellular reducing agent glutathione to
glutathione disulfide, in a cycle that appears to involve ligand-
centered reduction of the azo bond by glutathione forming an
hydrazo intermediate, followed by formation of glutathione
disulfide and regeneration of the azo bond. Catalytic drugs with
ligand-centered mechanisms might have the advantage of not
being so readily poisoned as metal-centered catalysts and there-
fore have greater potential for biological activity.
Materials and Methods
Materials. 4-(2-Pyridylazo)-N,N-dimethylaniline (azpy-NMe2), KI, NH4PF6, di-
chlorodihydrofluorescein diacetate, glutathione, and N-acetyl-L-cysteine
were purchased from Sigma-Aldrich and ascorbic acid from Alfa Aesar. Meth-
anol was anhydrous (Sigma-Aldrich) or dried over Mg/I2, and anhydrous DMF
(Aldrich) was used for electrochemical experiments. The starting materials
[(6-arene)RuCl2]2 (arenep-cymene, biphenyl) were prepared by reaction of
RuCl3xH2O with the reduced form of the arene (11), and the corresponding
iodido dimers [(6-arene)RuI2]2 from the reaction of [(6-arene)RuCl2]2 with
excess KI. The syntheses of 2-phenylazopyridine (azpy) and 4-(2-pyridylazo-
)phenol (azpy-OH) have been reported previously (13). Full details of the
synthesis and characterization of complexes are in the SI Text.
NMR Spectroscopy. NMR spectra were recorded on either a Bruker Avance 600
MHz equipped with either a TXI [1H, 13C, 15N] x,y,z-gradient probe or a TXI [1H,
13C, 15N] z-gradient cryoprobe, a Bruker Avance 800 MHz equipped with a TCI
[1H, 13C, 15N] z-gradient cryoprobe, or a Bruker DPX 360 MHz spectrometer
equipped with a QNP [1H, 13C, 15N] probe. 1H NMR signals were referenced to
the residual solvent,  7.27 (CDCl3), 2.52 (DMSO-d6), and for aqueous solutions
(containing D2O or H2O/D2O mixtures) dioxane was added as an internal
reference ( 3.75). The water resonance was suppressed by using a 1D double-
pulsed field gradient spin echo (DPFGSE) experiment (36) or presaturation
method. All spectra were recorded at 298 or 310 K and data were processed
by using XwinNMR (Version 3.6, Bruker).
X-Ray Crystallography.Diffraction data were collected at 150 K by using Mo K
radiation (  0.71073 Å) on a Bruker Smart Apex CCD diffractometer. The
crystal structure of 4 was solved by using Patterson methods (DIRDIF) (37) and
refined against F2 by using SHELXL-97 (38). The H atoms that are part of methyl
and hydroxyl groups were located in a difference map, and the groups treated
as rotating rigid bodies; other H atoms were placed in calculated positions.
Electrospray Mass Spectrometry. ESI-MS was obtained on a Micromass Plat-
form II mass spectrometer and solutions were infused directly. The capillary
voltage was 3.5 V and the cone voltage was typically varied between 10 and
45 V. The source temperature depended on the solvent used. Both positive and
negative ion modes were used (as appropriate).
UV-Vis Spectroscopy. A Perkin-Elmer Lambda-16 UV/Vis spectrophotometer
was used with 1-cm path length quartz cuvettes (0.5 ml) and a PTP1 Peltier
temperature controller. Spectra were recorded at 310 K and were processed
by using UV-Winlab software for Windows 95.
pHMeasurements. The pH values of aqueous solutions were measured at298
K by using a Corning pH meter 240 equipped with a Thermo micro combina-
tion KCl or KNO3 electrode calibrated with pH 4, pH 7, and pH 10 buffer
solutions (Sigma-Aldrich). The pH meter readings for D2O solutions were
recorded without correction for the effect of deuterium on the glass elec-
trode, and are termed pH*.
Cyclic Voltametry and Coulometry. Electrochemical studies were performed
with General Purpose Electrochemical System (GPES) Version 4.5 software
connected to an Autolab system containing a PSTAT20 potentiostat. All of the
electrochemical techniques used a three-electrode configuration. The refer-
ence electrode was Ag/AgCl in a solution of 0.1 M [TBA][BF4] in DMF against
which E1/2 for the ferrocinium/ferrocene couple was measured to be0.55 V.
The working and counter electrodes were a platinum microdisc (0.5-mm
diameter) and a large surface area platinum wire, respectively. Coulometric
experiments were performed in a conventional H-type cell by using large
surface-area Pt working and counter electrodes. All solutions were purged
with dry N2 before electrochemical study.
High Performance Liquid Chromatography (HPLC). A Hewlett–Packard series
1100 quaternary pump and a Rheodyne sample injector with a 1.0-ml loop, an
HP 1100 series UV-vis detector, and HP 1100 series Chemstation with an HP
enhanced integrator were used. Analytical separations were carried out on a
PLRP-S reversed-phase column (250 mm 7.5 mm, 100 Å, 8m, Polymer Labs)
with detection at 286 nm. The mobile phases were A, water (for HPLC
application, Fisher Chemicals) containing 0.1% TFAH; and B, acetonitrile (for
HPLC application, Fisher Chemicals) containing 0.1% TFAH. The flow rate was
3.5 mlmin1. The gradient (solvent B) was 10–50% over 30 min, 50–90% to 40
min.
Gas Chromatography (GC). A 5-Å molecular sieve column on an Agilent 7890A
GC system equipped with a thermal conductivity detector was used in at-
tempts to detect H2 with N2 as a carrier gas (for details and other methods see
SI Text).
IC50 Values. The concentration of the complexes that caused 50% inhibition of
the growth (IC50) was determined by using the sulforhodamine-B (SRB) assay
(39) as reported (13). For IC50 determinations on A549 cells with increased thiol
levels, cells were preincubated with 5 mM N-acetylcysteine for 2 h, a concen-
tration and time previously reported to be nontoxic for this cell line (40), and
confirmed by our controls. The N-acetylcysteine was removed, cells were
washed twice in PBS, fresh cell medium was added, and IC50 values were then
determined.
Detection of Reactive Oxygen Species (ROS) in A549 Cancer Cells. The detection
of ROS was based on earlier experimental protocols by Wang and Joseph (19)
with some modifications. The full procedure is reported in the SI Text.
Reactivity of Complexes 1–6 in Buffered Solutions. Solutions of ruthenium
complexes in MeOD were diluted in 10 mM phosphate buffer/D2O to give a
final concentration of 100M Ru (95% D2O, 5% MeOD) and NMR spectra were
recorded at 310 K after15 min and after 24 h. The pH* values of the samples
were 7.35 (1), 7.38 (2), 7.38 (3), 7.40 (4), 7.31 (5), and 7.32 (6), and the samples
were kept in the water bath at 310 K between NMR acquisitions. After 24 h,
ESIMS was obtained on samples of 1, 2, 4, and 5.
Substitution of Iodide by Chloride. Complex 4 was dissolved in water, sonicated
for 15 min to ensure dissolution, filtered, and then diluted to 30 M. NaCl
was added from a concentrated stock solution to give 100 mM NaCl and the
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corresponding UV-Vis absorbance spectrum was recorded at hourly intervals
over 24 h at 310 K.
UV-Vis Spectroscopy and HPLC of Reactions of Complexes 4 and 6 with GSH.
Buffers used were filtered through Chelex-100 to remove iron and degassed
by using N2/Ar before dissolving GSH. Solutions of GSH were made fresh for
each experiment and the pH adjusted to 7 with dilute NaOH/HCl, and the
solutions degassed again. Aliquots of complex 4 or 4-Cl in MeOH were added
to the GSH solution (final concentrations: 50 M Ru, 5 mM GSH, 10 mM
phosphate buffer; 95% H2O, 5% MeOH); the pH values were 7.06 (4) and 7.03
(4-Cl) for UV-Vis experiments and 7.88 (4) and 7.89 (4-Cl) for HPLC separations.
The rate of substitution of Ru-Cl/I by GS was determined by UV-Vis
spectroscopy, by fitting the change in absorbance at 597 nm with time (298 K)
to the appropriate equation for pseudo-first-order kinetics by using Origin
version 7.5 (OriginLab Corporation), to give the observed rate constant (kobs)
and the corresponding half-life (t1/2). The extent of substitution of Ru-Cl/I by
GS was followed by HPLC. The new fraction appearing over time was col-
lected and analyzed by ESI-MS.
Detection of GSH Oxidation to GSSG. Buffers were filtered through Chelex-100
to remove iron and degassed by using N2/Ar before dissolving GSH. After
dissolution the pH of the GSH solution was adjusted to7 by addition of dilute
NaOH/HCl and solutions were degassed again. Solutions of GSH were made
fresh for each experiment and aliquots of complexes 4 or 5 dissolved in
acetone-d6 were added [final concentrations 100 M Ru/ligand, GSH 10 mM
(when Ru present)/9.5 mM (just ligand), 30 mM phosphate buffer; 10% D2O,
85% H2O, 5% acetone-d6], the measured pH values were 7.62 (4), 7.57 (5), 7.55
(Azpy-NMe2), and 7.59 (Azpy-OH). Solutions of GSH alone (10/9.5 mM, 10%
D2O, 85% H2O, 5% acetone-d6) were also prepared at the same time [mea-
sured pH 7.40 (control for 4 and 5) and 7.60 (control for Azpy-NMe2 and
Azpy-OH)] to confirm minimal autooxidation of GSH, and these samples were
kept in a water bath at 310 K for 24 h, then the 1H NMR spectra were recorded.
After acquisition of NMR spectra, ESI mass spectra of samples were obtained
to confirm the presence of GSSG. The turnover frequency (TOF) was deter-
mined as the gradient of a plot of turnover number (TON) versus time. The
TON was determined as follows: TON  (IGSSG/{IGSH  IGSSG})([GSH]0/[Ru]),
where IGSSG/IGSH is the peak integral for oxidized/reduced glutathione, and
[GSH]0 is the initial concentration of GSH. ‘‘Quantofix’’ Peroxide Test Sticks
(Aldrich; detection range 1–100 mg H2O2 per liter) were used in attempts to
detect H2O2 during reactions of 5 (100 M, 10 mM GSH, 5% acetone-d6, 95%
H2O, 24 h incubation at 310 K).
For details of chemicals and biochemicals, synthesis and characterization of
complexes, and methods and techniques used, see SI Text.
ACKNOWLEDGMENTS. We thank Emily Jones and Daniel Cole (Oncosense
Ltd.) for assistance with the cytotoxicity tests; Lucy Moorcraft, Paul Murray,
Neil Robertson, and Lesley Yellowlees (University of Edinburgh) for assistance
with the electrochemistry; Colin Murrell and Gerald Chapman (University of
Warwick) for assistance with GC; Martin Wills and David Morris (University of
Warwick) for discussions on H2 detection and reaction mechanisms; and also
members of COST Action D39 for stimulating discussions. This work was
supported by a Biotechnology and Biological Sciences Research Council CASE
Award (to S.J.D.) and Oncosense Ltd.
1. Halpern J (2001) Organometallic chemistry at the threshold of a new millennium.
Retrospect and prospect. Pure Appl Chem 73:209–220.
2. Fish RH, Jaouen G (2003) Bioorganometallic chemistry: structural diversity of organo-
metallic complexes with bioligands and molecular recognition studies of several
supramolecular hosts with biomolecules, alkali-metal ions, and organometallic phar-
maceuticals. Organometallics 22:2166–2177.
3. Vessieres A, et al. (2005) Modification of the estrogenic properties of diphenols by the
incorporation of ferrocene. Generation of antiproliferative effects in vitro. J Med
Chem 48:3937–3940.
4. Ohkuma T, et al. (2006) The hydrogenation/transfer hydrogenation network: asym-
metric hydrogenation of ketones with chiral 6-arene/N-tosylethylenediamine-
ruthenium(II) catalysts. J Am Chem Soc 128:8724–8725.
5. Lo HC, Buriez O, Kerr JB, Fish RH (1999) Biorganometallic chemistry Part 11. Regio-
selective reduction of NADmodels with [Cp*Rh(bpy)H]: structure-activity relation-
ships and mechanistic aspects in the formation of the 1,4-NADH derivatives. Angew
Chem Int Ed 38:1429–1432.
6. Morris RE, et al. (2001) Inhibition of cancer cell growth by ruthenium(II) arene com-
plexes. J Med Chem 44:3616–3621.
7. Aird RE, et al. (2002) In vitro and in vivo activity and cross resistance profiles of novel
ruthenium (II) organometallic arene complexes in human ovarian cancer. Br J Cancer
86:1652–1657.
8. Wang F, et al. (2003) Kinetics of aquation and anation of ruthenium(II) arene antican-
cer complexes, acidity and X-ray structures of aqua adducts. Chem Eur J 9:5810–5820.
9. Novakova O, et al. (1995) Correlation between cytotoxicity and DNA binding of
polypyridyl ruthenium complexes. Biochemistry 34:12369–12378.
10. Hayward RL, et al. (2005) Investigation of the role of Bax, p21/Waf1 and p53 as
determinants of cellular responses in HCT116 colorectal cancer cells exposed to the
novel cytotoxic ruthenium(II) organometallic agent, RM175. Cancer Chemother Phar-
macol 55:577–583.
11. Habtemariam A, et al. (2006) Structure-activity relationships for cytotoxic rutheni-
um(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands. J Med Chem
49:6858–6868.
12. Wang F, et al. (2005) Controlling ligand substitution reactions of organometallic
complexes: tuning cancer cell cytotoxicity. Proc Natl Acad Sci USA 102:18269–18274.
13. Dougan SJ, Melchart M, Habtemariam A, Parsons S, Sadler PJ (2006) Phenylazo-
pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss,
aquation, and cancer cell cytotoxicity. Inorg Chem 45:10882–10894.
14. Goswami S, Mukherjee RN, Chakravorty A (1983) Chemistry of ruthenium. 12. Reac-
tions of bidentate ligands with diaquabis[2-(arylazo)pyridine]ruthenium(II) cation.
Stereoretentive synthesis of tris chelates and their characterization: metal oxidation,
ligand reduction, and spectroelectrochemical correlation. Inorg Chem 22:2825–2832.
15. Goswami S, Chakravarty AR, Chakravorty A (1983) Chemistry of ruthenium. 7. Aqua
complexes of isomeric bis[(2-arylazo)pyridine]ruthenium(II) moieties and their reac-
tions: solvolysis, protic equilibriums, and electrochemistry. Inorg Chem 22:602–609.
16. Krause RA, Krause K (1984) Chemistry of bipyridyl-like ligands. 3. Complexes of
ruthenium(II) with 2-((4-nitrophenyl)azo)pyridine. Inorg Chem 23:2195–2198.
17. Patai S, ed (1975) TheChemistry ofHydrazo,AzoandAzoxyGroups (Wiley, Bristol, UK).
18. Meister A, Anderson ME (1983) Glutathione. Annu Rev Biochem 52:711–760.
19. Wang H, Joseph JA (1999) Quantifying cellular oxidative stress by dichlorofluorescein
assay using microplate reader. Free Radical Biol Med 27:612–616.
20. Halliwell B, Whiteman M (2004) Measuring reactive species and oxidative damage in
vivo and in cell culture: How should you do it and what do the results mean? Br J
Pharmacol 142:231–255.
21. Zhang CX, Lippard SJ (2003) New metal complexes as potential therapeutics. Curr Opin
Chem Biol 7:481–489.
22. Yan YK, Melchart M, Habtemariam A, Peacock AFA, Sadler PJ (2006) Catalysis of
regioselective reduction of NAD by ruthenium(II) arene complexes under biologically
relevant conditions. J Biol Inorg Chem 11:483–488.
23. Balendiran GK, Dabur R, Fraser D (2004) Role of glutathione in cancer. Cell Biochem
Funct 22:343–352.
24. Bose RN (2002) Biomolecular targets for platinum antitumor drugs. Mini-Rev Med
Chem 2:103–111.
25. Santra BK, Lahiri GK (1997) Cobalt-mediated direct and selective aromatic thiolation in
the complex [CoIII(o-SC6H4NNC5H4N)2]ClO4. Synthesis, spectroscopic characterisation
and electron-transfer properties. J Chem Soc Dalton Trans 1883–1888.
26. Kosower EM, Kosower NS (1969) Lest I forget thee, glutathione. Nature 224:117–120.
27. Kosower EM, Miyadera T (1972) Glutathione. 6. Probable mechanism of action of
diazene antibiotics. J Med Chem 15:307–312.
28. Hansen JC (1996) The iodide-catalyzed decomposition of hydrogen peroxide: A simple
computer-interfaced kinetics experiment for general chemistry J Chem Educ 73:728–
732, .
29. Renschler MF (2004) The emerging role of reactive oxygen species in cancer therapy.
Eur J Cancer 40:1934–1940.
30. Gomes A, Fernandes E, Lima JLFC (2005) Fluorescence probes used for detection of
reactive oxygen species. J Biochem Biophys Methods 65:45–80.
31. Aruoma OI, Halliwell B, Hoey BM., Butler J (1989) The antioxidant action of N-acetyl-
cysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hy-
pochlorous acid. Free Radical Biol Med 6:593–597.
32. Agostinelli E, Seiler N (2006) Non-irradiation-derived reactive oxygen species (ROS) and
cancer: Therapeutic implications. Amino Acids 31:341–355.
33. DeAtley SM, et al. (1999) Antioxidants protect against reactive oxygen species associ-
ated with adriamycin-treated cardiomyocytes. Cancer Lett 136:41–46.
34. Chou W-C, et al. (2004) Role of NADPH oxidase in arsenic-induced reactive oxygen
species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci USA
101:4578–4583.
35. Siomek A, et al. (2006) Severe oxidatively damaged DNA after cisplatin treatment of
cancer patients. Int J Cancer 119:2228–2230.
36. Hwang T-L, Shaka AJ (1995) Water suppression that works. Excitation sculpting using
arbitrary wave-forms and pulsed-field gradients. J Magn Reson Ser A 112:275–279.
37. Beurskens PT, et al. (1999) The DIRDIF-99 program system (Crystallography Laboratory,
University of Nijmegen, The Netherlands).
38. Sheldrick GM (1997) SHELXL-97 (University of Go¨ttingen, Go¨ttingen, Germany).
39. Skehan P, et al. (1990) New colorimetric cytotoxicity assay for anticancer-drug screen-
ing. J Natl Cancer Inst 82:1107–1112.
40. Moodie FM, et al. (2004) Oxidative stress and cigarette smoke alter chromatin remod-
eling but differentially regulate NF-kappaB activation and proinflammatory cytokine
release in alveolar epithelial cells. FASEB J 18:1897–1899.
Dougan et al. PNAS  August 19, 2008  vol. 105  no. 33  11633
CH
EM
IS
TR
Y
